Fig. 4From: Ibrutinib protects T cells in patients with CLL from proliferation-induced senescenceIbrutinib normalises exhaustion marker expression on CLL patient T cells in vitro. PBMC from Healthy Donor (HD, n = 4) or treatment naive CLL patients (n = 4) were stained with CTV, treated with ibrutinib, zanubrutinib, or acalabrutinib or DMSO, and stimulated with T cell activation beads. Expression of PD-1, TIM3 and LAG3 was determined on days 3, 5 and 7Back to article page